Furthermore, recent studies approved that eIF6 was dysregulated in various cancers, such as malignant pleural mesothelioma (MPM) [20], Gallbladder cancer (GBC) [43], ovarian serous carcinoma (OV) [21], colorectal cancer (CRC) [19] and non-small cell lung cancer (NSCLC) [23]. This evidence concerns the gene EIF6 and ovarian serous carcinoma.